Gilead Sciences Stock Rating Reaffirmed by TheStreet (GILD)
Gilead Sciences (NASDAQ:GILD)‘s stock had its “buy” rating reiterated by stock analysts at TheStreet in a report issued on Monday, American Banking & Market News reports.
The analysts wrote, “Gilead (GILD) has been reiterated by TheStreet Ratings as a buy with a ratings score of A-. The company’s strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance, reasonable valuation levels, increase in net income and expanding profit margins. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results.”
Gilead Sciences (NASDAQ:GILD) opened at 82.99 on Monday. Gilead Sciences has a 52-week low of $41.69 and a 52-week high of $84.40. The stock’s 50-day moving average is $78.98 and its 200-day moving average is $69.51. The company has a market cap of $127.3 billion and a P/E ratio of 45.63.
Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Tuesday, February 4th. The company reported $0.55 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.50 by $0.05. The company had revenue of $3.04 billion for the quarter, compared to the consensus estimate of $2.85 billion. During the same quarter in the prior year, the company posted $0.50 earnings per share. The company’s quarterly revenue was up 20.5% on a year-over-year basis. On average, analysts predict that Gilead Sciences will post $3.77 earnings per share for the current fiscal year.
A number of other firms have also recently commented on GILD. Analysts at Barclays raised their price target on shares of Gilead Sciences from $90.00 to $95.00 in a research note on Friday. They now have an “overweight” rating on the stock. Separately, analysts at Argus raised their price target on shares of Gilead Sciences from $84.00 to $90.00 in a research note on Monday, February 10th. They now have a “buy” rating on the stock. Finally, analysts at Deutsche Bank reiterated a “buy” rating on shares of Gilead Sciences in a research note on Wednesday, February 5th. They now have a $132.00 price target on the stock. Two research analysts have rated the stock with a hold rating and twenty-six have issued a buy rating to the company. Gilead Sciences currently has an average rating of “Buy” and a consensus target price of $85.73.
In other Gilead Sciences news, Director Nicholas Moore unloaded 19,068 shares of the company’s stock in a transaction dated Wednesday, February 19th. The stock was sold at an average price of $83.12, for a total transaction of $1,584,932.16. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
Gilead Sciences, Inc (NASDAQ:GILD) is a research-based biopharmaceutical company that discovers, develops and commercializes medicines.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.